ImmunityBio (NASDAQ:IBRX – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other brokerages also recently issued reports on IBRX. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of ImmunityBio in a research report on Thursday, October 15th. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective on shares of ImmunityBio in a report on Wednesday, October 14th. Jefferies Financial Group upped their target price on shares of ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.
Check Out Our Latest Stock Analysis on IBRX
ImmunityBio Price Performance
IBRX stock opened at $6.02 on Friday. ImmunityBio has a 52-week low of $1.95 and a 52-week high of $12.43. The stock has a market cap of $6.40 billion, a price-to-earnings ratio of -5.57 and a beta of 0.17. The business has a fifty day moving average of $8.59 and a two-hundred day moving average of $7.96.
Insider Buying and Selling
In other news, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director directly owned 2,777,788 shares in the company, valued at $29,861,221. This trade represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by insiders.
Hedge Funds Weigh In On ImmunityBio
Several hedge funds have recently bought and sold shares of IBRX. Compass Wealth Management LLC acquired a new position in ImmunityBio in the 3rd quarter valued at about $29,000. Markowski Investments purchased a new stake in ImmunityBio during the second quarter worth about $29,000. GAMMA Investing LLC increased its stake in ImmunityBio by 262.2% during the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock worth $36,000 after purchasing an additional 2,756 shares during the period. Hollencrest Capital Management acquired a new stake in shares of ImmunityBio during the second quarter worth about $44,000. Finally, Western Wealth Management LLC acquired a new stake in shares of ImmunityBio during the first quarter worth about $44,000. Institutional investors and hedge funds own 8.58% of the company’s stock.
ImmunityBio Company Profile
ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
See Also
- Five stocks we like better than ImmunityBio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
